A Phase 1, Single-center, Open-label, Study to Investigate the Safety, Tolerability, and Pharmacokinetics of a Single Dose and Multiple Doses of EDG-7500 in Healthy Adult Caucasian and Japanese Participants
Latest Information Update: 10 Mar 2026
At a glance
- Drugs EDG-7500 (Primary)
- Indications Cardiovascular disorders; Hypertrophic cardiomyopathy; Kidney disorders
- Focus Pharmacokinetics
- Sponsors Edgewise Therapeutics
Most Recent Events
- 10 Mar 2026 New trial record